Publications 2024

Alirezaylavasani A, Skeie LG, Egner IM, Chopra A, Dahl TB, Prebensen C, Vaage JT, Halvorsen B, Lund-Johansen F, Tonby K, Reikvam DH, Stiksrud B, Holter JC, Dyrhol-Riise AM, Munthe LA, Kared H (2024)
Vaccine responses and hybrid immunity in people living with HIV after SARS-CoV-2 breakthrough infections
NPJ Vaccines, 9 (1), 185
DOI 10.1038/s41541-024-00972-3, PubMed 39384763

Alonso-Rodríguez N, Vianello E, van Veen S, Jenum S, Tonby K, van Riessen R, Lai X, Mortensen R, Ottenhoff THM, Dyrhol-Riise AM (2024)
Whole blood RNA signatures in tuberculosis patients receiving H56:IC31 vaccine as adjunctive therapy
Front Immunol, 15, 1350593
DOI 10.3389/fimmu.2024.1350593, PubMed 38433842

Barratt-Due A, Pettersen K, Børresdatter-Dahl T, Holter JC, Grønli RH, Dyrhol-Riise AM, Lerum TV, Holten AR, Tonby K, Trøseid M, Skjønsberg OH, Granerud BK, Heggelund L, Kildal AB, Schjalm C, Aaløkken TM, Aukrust P, Ueland T, Mollnes TE, Halvorsen B, NOR‐Solidarity study groupThe Norwegian SARS‐CoV‐2 study group (2024)
Escalated complement activation during hospitalization is associated with higher risk of 60-day mortality in SARS-CoV-2-infected patients
J Intern Med, 296 (1), 80-92
DOI 10.1111/joim.13783, PubMed 38539241

Grønmo MM, Møller-Stray J, Akselsen PE, Lindemann PC, Fostervold A, Knudsen CV, Knudsen PK, Lindbæk M, Tonby K, Sundsfjord A (2024)
Gentamicin should remain part of the empirical sepsis regimen for adults
Tidsskr Nor Laegeforen, 144 (3)
DOI 10.4045/tidsskr.23.0659, PubMed 38415563

Hites M, Massonnaud CR, Lapique EL, Belhadi D, Jamard S, Goehringer F, Danion F, Reignier J, de Castro N, Garot D, Lacombe K, Tolsma V, Faure E, Malvy D, Staub T, Courjon J, Cazenave-Roblot F, Dyrhol Riise AM, Leturnier P, Martin-Blondel G, Roger C, Akinosoglou K, Moing VL, Piroth L, Sellier P et al. (2024)
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial
J Infect, 88 (3), 106120
DOI 10.1016/j.jinf.2024.106120, PubMed 38367705

Mortensen R, Clemmensen HS, Woodworth JS, Therkelsen ML, Mustafa T, Tonby K, Jenum S, Agger EM, Dyrhol-Riise AM, Andersen P (2024)
Author Correction: Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice
Commun Biol, 7 (1), 662
DOI 10.1038/s42003-024-06260-z, PubMed 38811662

Nore KG, Louet C, Bugge M, Gidon A, Jørgensen MJ, Jenum S, Dyrhol-Riise AM, Tonby K, Flo TH (2024)
The Cyclooxygenase 2 Inhibitor Etoricoxib as Adjunctive Therapy in Tuberculosis Impairs Macrophage Control of Mycobacterial Growth
J Infect Dis, 229 (3), 888-897
DOI 10.1093/infdis/jiad390, PubMed 37721470

Viermyr HK, Halvorsen B, Sagen EL, Michelsen AE, Barrat-Due A, Kåsine T, Nezvalova-Henriksen K, Dyrhol-Riise AM, Nor‐Solidarity Consortium, Lerum TV, Müller F, Tonby K, Tveita A, Aukrust P, Trøseid M, Ueland T, Dahl TB (2024)
High viral loads combined with inflammatory markers predict disease severity in hospitalized COVID-19 patients: Results from the NOR-Solidarity trial
J Intern Med, 296 (3), 249-259
DOI 10.1111/joim.13820, PubMed 39011800

Publications 2023

Mohn KG, Bredholt G, Onyango TB, Brokstad KA, Zhou F, Holter JC, Tonby K, Dyrhol-Riise AM, Cox RJ, Bergen COVID-19 Research Group, Norwegian SARS-CoV-2 Study Group (2023)
SARS-CoV-2 infection induces long-lived B and T-cell responses up to 15 months post-infection, irrespective of disease severity
J Infect, 87 (4), 346-349
DOI 10.1016/j.jinf.2023.05.023, PubMed 37295510

Murphy SL, Halvorsen B, Holter JC, Huse C, Tveita A, Trøseid M, Hoel H, Kildal AB, Holten AR, Lerum TV, Skjønsberg OH, Michelsen AE, Aaløkken TM, NOR-SOLIDARITY Consortium, The Norwegian SARS-CoV-2 study group investigators, Tonby K, Lind A, Dudman S, Granerud BK, Heggelund L, Bøe S, Dyrholt-Riise AM, Aukrust P, Barratt-Due A, Ueland T, Dahl TB (2023)
Circulating markers of extracellular matrix remodelling in severe COVID-19 patients
J Intern Med, 294 (6), 784-797
DOI 10.1111/joim.13725, PubMed 37718572

Quiles-Jiménez A, Sousa MML, Huse C, Dyrhol-Riise AM, Holter JC, Christensen EE, Tonby K, Holten AR, Aukrust P, Bjørås M, Dahl TB, Halvorsen B (2023)
Severely ill COVID-19 patients have altered circulating levels of proteins controlling the epitranscriptome
J Infect, 86 (6), 593-595
DOI 10.1016/j.jinf.2023.03.002, PubMed 36889510

Trøseid M, Arribas JR, Assoumou L, Holten AR, Poissy J, Terzić V, Mazzaferri F, Baño JR, Eustace J, Hites M, Joannidis M, Paiva JA, Reuter J, Püntmann I, Patrick-Brown TDJH, Westerheim E, Nezvalova-Henriksen K, Beniguel L, Dahl TB, Bouscambert M, Halanova M, Péterfi Z, Tsiodras S, Rezek M, Briel M et al. (2023)
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial
Crit Care, 27 (1), 9
DOI 10.1186/s13054-022-04205-8, PubMed 36627655

Trøseid M, Holter JC, Holm K, Vestad B, Sazonova T, Granerud BK, Dyrhol-Riise AM, Holten AR, Tonby K, Kildal AB, Heggelund L, Tveita A, Bøe S, Müller KE, Jenum S, Hov JR, Ueland T, Norwegian SARS-CoV-2 study group (2023)
Gut microbiota composition during hospitalization is associated with 60-day mortality after severe COVID-19
Crit Care, 27 (1), 69
DOI 10.1186/s13054-023-04356-2, PubMed 36814280

Publications 2022

Chendi BH, Jooste T, Scriba TJ, Kidd M, Mendelsohn S, Tonby K, Walzl G, Dyrhol-Riise AM, Chegou NN (2022)
Utility of a three-gene transcriptomic signature in the diagnosis of tuberculosis in a low-endemic hospital setting
Infect Dis (Lond), 55 (1), 44-54
DOI 10.1080/23744235.2022.2129779, PubMed 36214761

Christensen EE, Binde C, Leegaard M, Tonby K, Dyrhol-Riise AM, Kvale D, Amundsen EK, Holten AR (2022)
DIAGNOSTIC ACCURACY AND ADDED VALUE OF INFECTION BIOMARKERS IN PATIENTS WITH POSSIBLE SEPSIS IN THE EMERGENCY DEPARTMENT
Shock, 58 (4), 251-259
DOI 10.1097/SHK.0000000000001981, PubMed 36130401

Degenhardt F, Ellinghaus D, Juzenas S, Lerga-Jaso J, Wendorff M, Maya-Miles D, Uellendahl-Werth F, ElAbd H, Rühlemann MC, Arora J, Özer O, Lenning OB, Myhre R, Vadla MS, Wacker EM, Wienbrandt L, Blandino Ortiz A, de Salazar A, Garrido Chercoles A, Palom A, Ruiz A, Garcia-Fernandez AE, Blanco-Grau A, Mantovani A, Zanella A et al. (2022)
Detailed stratified GWAS analysis for severe COVID-19 in four European populations
Hum Mol Genet, 31 (23), 3945-3966
DOI 10.1093/hmg/ddac158, PubMed 35848942

Trøseid M, Dahl TB, Holter JC, Kildal AB, Murphy SL, Yang K, Quiles-Jiménez A, Heggelund L, Müller KE, Tveita A, Michelsen AE, Bøe S, Holten AR, Hoel H, Mathiessen A, Aaløkken TM, Fevang B, Granerud BK, Tonby K, Henriksen KN, Lerum TV, Müller F, Skjønsberg OH, Barratt-Due A, Dyrhol-Riise AM et al. (2022)
Persistent T-cell exhaustion in relation to prolonged pulmonary pathology and death after severe COVID-19: Results from two Norwegian cohort studies
J Intern Med, 292 (5), 816-828
DOI 10.1111/joim.13549, PubMed 35982589

Tveita A, Murphy SL, Holter JC, Kildal AB, Michelsen AE, Lerum TV, Kaarbø M, Heggelund L, Holten AR, Finbråten AK, Müller KE, Mathiessen A, Bøe S, Fevang B, Granerud BK, Tonby K, Lind A, Dudman SG, Henriksen KN, Müller F, Skjønsberg OH, Trøseid M, Barratt-Due A, Dyrhol-Riise AM, Aukrust P et al. (2022)
High Circulating Levels of the Homeostatic Chemokines CCL19 and CCL21 Predict Mortality and Disease Severity in COVID-19
J Infect Dis, 226 (12), 2150-2160
DOI 10.1093/infdis/jiac313, PubMed 35876699

Vestad B, Ueland T, Lerum TV, Dahl TB, Holm K, Barratt-Due A, Kåsine T, Dyrhol-Riise AM, Stiksrud B, Tonby K, Hoel H, Olsen IC, Henriksen KN, Tveita A, Manotheepan R, Haugli M, Eiken R, Berg Å, Halvorsen B, Lekva T, Ranheim T, Michelsen AE, Kildal AB, Johannessen A, Thoresen L et al. (2022)
Respiratory dysfunction three months after severe COVID-19 is associated with gut microbiota alterations
J Intern Med, 291 (6), 801-812
DOI 10.1111/joim.13458, PubMed 35212063

Waagsbø B, Espvik HJ, Høgli JU, Tonby K, Kleppe LKS (2022)
[We need a new action plan for antibiotic resistance]
Tidsskr Nor Laegeforen, 142 (11)
DOI 10.4045/tidsskr.22.0279, PubMed 35997193

Publications 2021

Barratt-Due A, Olsen IC, Nezvalova-Henriksen K, Kåsine T, Lund-Johansen F, Hoel H, Holten AR, Tveita A, Mathiessen A, Haugli M, Eiken R, Kildal AB, Berg Å, Johannessen A, Heggelund L, Dahl TB, Skåra KH, Mielnik P, Le LAK, Thoresen L, Ernst G, Hoff DAL, Skudal H, Kittang BR, Olsen RB et al. (2021)
Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial
Ann Intern Med, 174 (9), 1261-1269
DOI 10.7326/M21-0653, PubMed 34251903

Chendi BH, Snyders CI, Tonby K, Jenum S, Kidd M, Walzl G, Chegou NN, Dyrhol-Riise AM (2021)
A Plasma 5-Marker Host Biosignature Identifies Tuberculosis in High and Low Endemic Countries
Front Immunol, 12, 608846
DOI 10.3389/fimmu.2021.608846, PubMed 33732236

Chendi BH, Tveiten H, Snyders CI, Tonby K, Jenum S, Nielsen SD, Hove-Skovsgaard M, Walzl G, Chegou NN, Dyrhol-Riise AM (2021)
CCL1 and IL-2Ra differentiate Tuberculosis disease from latent infection Irrespective of HIV infection in low TB burden countries
J Infect, 83 (4), 433-443
DOI 10.1016/j.jinf.2021.07.036, PubMed 34333033

Christensen EE, Jørgensen MJ, Nore KG, Dahl TB, Yang K, Ranheim T, Huse C, Lind A, Nur S, Stiksrud B, Jenum S, Tonby K, Holter JC, Holten AR, Halvorsen B, Dyrhol-Riise AM (2021)
Critical COVID-19 is associated with distinct leukocyte phenotypes and transcriptome patterns
J Intern Med, 290 (3), 677-692
DOI 10.1111/joim.13310, PubMed 34080738

Jenum S, Tonby K, Rueegg CS, Rühwald M, Kristiansen MP, Bang P, Olsen IC, Sellæg K, Røstad K, Mustafa T, Taskén K, Kvale D, Mortensen R, Dyrhol-Riise AM (2021)
A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients
Nat Commun, 12 (1), 6774
DOI 10.1038/s41467-021-27029-6, PubMed 34811370

Jøntvedt Jørgensen M, Nore KG, Aass HCD, Layre E, Nigou J, Mortensen R, Tasken K, Kvale D, Jenum S, Tonby K, Dyrhol-Riise AM (2021)
Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients
Front Cell Infect Microbiol, 11, 669623
DOI 10.3389/fcimb.2021.669623, PubMed 34307194

Kolberg ES, Wickstrøm K, Tonby K, Dyrhol-Riise AM, Holten AR, Amundsen EK (2021)
Serum ACE as a prognostic biomarker in COVID-19: a case series
APMIS, 129 (4), 237-238
DOI 10.1111/apm.13108, PubMed 33368687

Kåsine T, Dyrhol-Riise AM, Barratt-Due A, Kildal AB, Olsen IC, Nezvalova-Henriksen K, Lund-Johansen F, Hoel H, Holten AR, Tveita A, Mathiessen A, Haugli M, Eiken R, Berg Å, Johannessen A, Heggelund L, Dahl TB, Halvorsen B, Mielnik P, Le LAK, Thoresen L, Ernst G, Hoff DAL, Skudal H, Kittang BR et al. (2021)
Neutrophil count predicts clinical outcome in hospitalized COVID-19 patients: Results from the NOR-Solidarity trial
J Intern Med, 291 (2), 241-243
DOI 10.1111/joim.13377, PubMed 34411368

Lerum TV, Aaløkken TM, Brønstad E, Aarli B, Ikdahl E, Lund KMA, Durheim MT, Rodriguez JR, Meltzer C, Tonby K, Stavem K, Skjønsberg OH, Ashraf H, Einvik G (2021)
Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19
Eur Respir J, 57 (4)
DOI 10.1183/13993003.03448-2020, PubMed 33303540

Watne LO, Tonby K, Holten AR, Olasveengen TM, Romundstad LG, Neerland BE (2021)
Delirium is common in patients hospitalized with COVID-19
Intern Emerg Med, 16 (7), 1997-2000
DOI 10.1007/s11739-021-02715-x, PubMed 33830418

Wickstrøm KE, Vitelli V, Carr E, Holten AR, Bendayan R, Reiner AH, Bean D, Searle T, Shek A, Kraljevic Z, Teo J, Dobson R, Tonby K, Köhn-Luque A, Amundsen EK (2021)
Regional performance variation in external validation of four prediction models for severity of COVID-19 at hospital admission: An observational multi-centre cohort study
PLoS One, 16 (8), e0255748
DOI 10.1371/journal.pone.0255748, PubMed 34432797

Aamodt AH, Høgestøl EA, Popperud TH, Holter JC, Dyrhol-Riise AM, Tonby K, Stiksrud B, Quist-Paulsen E, Berge T, Barratt-Due A, Aukrust P, Heggelund L, Blennow K, Zetterberg H, Harbo HF (2021)
Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19
J Neurol, 268 (10), 3574-3583
DOI 10.1007/s00415-021-10517-6, PubMed 33743046

Publications 2020

Borén HK, Thaulow CM, Quist-Paulsen E, Wæhre T, Akselsen PE, Tonby K (2020)
[Antibiotic use in hospitals in cases of COVID-19]
Tidsskr Nor Laegeforen, 140 (11)
DOI 10.4045/tidsskr.20.0443, PubMed 32815355

Gundem T, Olasveengen TM, Hovda KE, Gaustad K, Schøndorf C, Rostrup M, Frøyshov S, Undseth Ø, Tonby K, Holten AR, Sunde K (2020)
Ventilatory support for hypoxaemic intensive care patients with COVID-19
Tidsskr Nor Laegeforen, 140 (11)
DOI 10.4045/tidsskr.20.0445, PubMed 32815344

Gundem T, Olasveengen TM, Hovda KE, Gaustad K, Schøndorf C, Rostrup M, Frøyshov S, Undseth Ø, Tonby K, Holten AR, Sunde K (2020)
[T.M. Gundem and colleagues respond]
Tidsskr Nor Laegeforen, 140 (12)
DOI 10.4045/tidsskr.20.0650, PubMed 32900164

Holten AR, Nore KG, Tveiten CEVWK, Olasveengen TM, Tonby K (2020)
Predicting severe COVID-19 in the Emergency Department
Resusc Plus, 4, 100042
DOI 10.1016/j.resplu.2020.100042, PubMed 33403367

Holter JC, Pischke SE, de Boer E, Lind A, Jenum S, Holten AR, Tonby K, Barratt-Due A, Sokolova M, Schjalm C, Chaban V, Kolderup A, Tran T, Tollefsrud Gjølberg T, Skeie LG, Hesstvedt L, Ormåsen V, Fevang B, Austad C, Müller KE, Fladeby C, Holberg-Petersen M, Halvorsen B, Müller F, Aukrust P et al. (2020)
Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients
Proc Natl Acad Sci U S A, 117 (40), 25018-25025
DOI 10.1073/pnas.2010540117, PubMed 32943538

Jøntvedt Jørgensen M, Holter JC, Christensen EE, Schjalm C, Tonby K, Pischke SE, Jenum S, Skeie LG, Nur S, Lind A, Opsand H, Enersen TB, Grøndahl R, Hermann A, Dudman S, Muller F, Ueland T, Mollnes TE, Aukrust P, Heggelund L, Holten AR, Dyrhol-Riise AM (2020)
Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19
Sci Rep, 10 (1), 21697
DOI 10.1038/s41598-020-78710-7, PubMed 33303843

Jøntvedt Jørgensen M, Jenum S, Tonby K, Mortensen R, Walzl G, Du Plessis N, Dyrhol-Riise AM (2020)
Monocytic myeloid-derived suppressor cells reflect tuberculosis severity and are influenced by cyclooxygenase-2 inhibitors
J Leukoc Biol, 110 (1), 177-186
DOI 10.1002/JLB.4A0720-409RR, PubMed 33155730

Nore KG, Jørgensen MJ, Dyrhol-Riise AM, Jenum S, Tonby K (2020)
Elevated Levels of Anti-Inflammatory Eicosanoids and Monocyte Heterogeneity in Mycobacterium tuberculosis Infection and Disease
Front Immunol, 11, 579849
DOI 10.3389/fimmu.2020.579849, PubMed 33304347

Ueland T, Heggelund L, Lind A, Holten AR, Tonby K, Michelsen AE, Jenum S, Jørgensen MJ, Barratt-Due A, Skeie LG, Nordøy I, Aanensen Fraz MS, Quist-Paulsen E E, Pischke SE, Johal SK, Hesstvedt L, Bogen M, Fevang B, Halvorsen B, Müller F, Bekken GK, Mollnes TE, Dudman S, Aukrust P, Dyrhol-Riise AM et al. (2020)
Elevated plasma sTIM-3 levels in patients with severe COVID-19
J Allergy Clin Immunol, 147 (1), 92-98
DOI 10.1016/j.jaci.2020.09.007, PubMed 32971109

Publications 2019

Mortensen R, Clemmensen HS, Woodworth JS, Therkelsen ML, Mustafa T, Tonby K, Jenum S, Agger EM, Dyrhol-Riise AM, Andersen P (2019)
Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice
Commun Biol, 2, 288
DOI 10.1038/s42003-019-0530-3, PubMed 31396568

Tonby K, Mortensen R, Ruhwald M, Dyrhol-Riise AM, Jenum S (2019)
KLRG1-Expressing CD4 T Cells Are Reduced in Tuberculosis Patients Compared to Healthy Mycobacterium tuberculosis-Infected Subjects, but Increase With Treatment
J Infect Dis, 220 (1), 174-176
DOI 10.1093/infdis/jiz056, PubMed 30888024

Publications 2016

Tonby K, Wergeland I, Lieske NV, Kvale D, Tasken K, Dyrhol-Riise AM (2016)
The COX- inhibitor indomethacin reduces Th1 effector and T regulatory cells in vitro in Mycobacterium tuberculosis infection
BMC Infect Dis, 16 (1), 599
DOI 10.1186/s12879-016-1938-8, PubMed 27776487

Publications 2015

Feruglio SL, Tonby K, Kvale D, Dyrhol-Riise AM (2015)
Early dynamics of T helper cell cytokines and T regulatory cells in response to treatment of active Mycobacterium tuberculosis infection
Clin Exp Immunol, 179 (3), 454-65
DOI 10.1111/cei.12468, PubMed 25313008

Lieske NV, Tonby K, Kvale D, Dyrhol-Riise AM, Tasken K (2015)
Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells with MEK/ERK Signaling Pathway Inhibitors
PLoS One, 10 (11), e0141903
DOI 10.1371/journal.pone.0141903, PubMed 26544592

Tonby K, Ruhwald M, Kvale D, Dyrhol-Riise AM (2015)
IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection
Sci Rep, 5, 9223
DOI 10.1038/srep09223, PubMed 25783975

Wergeland I, Pullar N, Assmus J, Ueland T, Tonby K, Feruglio S, Kvale D, Damås JK, Aukrust P, Mollnes TE, Dyrhol-Riise AM (2015)
IP-10 differentiates between active and latent tuberculosis irrespective of HIV status and declines during therapy
J Infect, 70 (4), 381-91
DOI 10.1016/j.jinf.2014.12.019, PubMed 25597826

Publications 2014

Pullar ND, Steinum H, Tonby K, Heggelund L, Leiva RA, Ofstad R, Bruun JN, Dyrhol-Riise AM (2014)
Low prevalence of positive interferon-gamma tests in HIV-positive long-term immigrants in Norway
Int J Tuberc Lung Dis, 18 (2), 180-7
DOI 10.5588/ijtld.13.0276, PubMed 24429310